Image
illustration
Venture Capital New Investment

MRM HEALTH Announces First Patient Dosed with MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

Wednesday 8 December, 2021
Body

MRM Health’s MH002-UC-201 study is a multi-center, double-blind, randomized, placebo-controlled trial in multiple clinical sites in Belgium, Poland and Czech Republic and will enrol 45 mild-to-moderate UC patients.

Content